Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma.

Immunity - 21 Feb 2017

George Suzanne, Miao Diana, Demetri George D, Adeegbe Dennis, Rodig Scott J, Shukla Sachet, Lipschitz Mikel, Amin-Mansour Ali, Raut Chandrajit P, Carter Scott L, Hammerman Peter, Freeman Gordon J, Wu Catherine J, Ott Patrick A, Wong Kwok-Kin, Van Allen Eliezer M

Abstract excerpt

Response to immune checkpoint blockade in mesenchymal tumors is poorly characterized, but immunogenomic dissection of these cancers could inform immunotherapy mediators. We identified a treatment-naive patient who has metastatic uterine leiomyosarcoma and has experienced complete tumor remission for >2 years on anti-PD-1 (pembrolizumab) monotherapy. We analyzed the primary tumor, the sole treatment-resistant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Leiomyosarcoma

Share to Programmed Cell Death 1 Receptor

Share to PTEN Phosphohydrolase

Share to Transcriptome

Share to Uterine Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 28228279
DOI: 10.1016/j.immuni.2017.02.001
PMCID: PMC5408320

Genes

PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma.PMID 28228279Read ↗

Genomic Approaches to Understanding Response and Resistance to Immunotherapy.Semantic proximity Read ↗

Proteogenomic profiling of soft tissue leiomyosarcoma reveals distinct molecular subtypes with divergent outcomes and therapeutic vulnerabilitiesSemantic proximity Read ↗

Tumor-myeloid crosstalk drives therapy resistance in localized bladder cancerSemantic proximity Read ↗

PD-L1 expression in 522 selected sarcomas with subset analysis of recurrent or metastatic matched samples and association with tumour-infiltrating lymphocytesSemantic proximity Read ↗

The Future of Targeted Therapy for LeiomyosarcomaSemantic proximity Read ↗

The Role of PTEN Loss in Immune Escape, Melanoma Prognosis and Therapy ResponseSemantic proximity Read ↗

Spatial and Temporal Changes in PD-L1 Expression in Cancer: The Role of Genetic Drivers, Tumor Microenvironment and Resistance to TherapySemantic proximity Read ↗

Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement.Semantic proximity Read ↗

Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti–PD-1 + Antiangiogenesis in Malignant Pleural MesotheliomaSemantic proximity Read ↗

Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibitionSemantic proximity Read ↗

Genomic landscape of lymphatic malformations: a case series and response to the PI3Kα inhibitor alpelisib in an N-of-1 clinical trial.Semantic proximity Read ↗

Distinct immunologic patterns of response and resistance to anti-PD-1/PD-L1-based immunotherapy in patients with soft tissue sarcoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.